Paradigm Biocapital Advisors LP Has $42.59 Million Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Paradigm Biocapital Advisors LP boosted its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 32.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,304,970 shares of the company's stock after buying an additional 1,801,370 shares during the quarter. Olema Pharmaceuticals makes up about 1.5% of Paradigm Biocapital Advisors LP's investment portfolio, making the stock its 16th largest position. Paradigm Biocapital Advisors LP owned 12.75% of Olema Pharmaceuticals worth $42,588,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of OLMA. Barclays PLC boosted its stake in Olema Pharmaceuticals by 105.0% in the 3rd quarter. Barclays PLC now owns 94,915 shares of the company's stock valued at $1,133,000 after buying an additional 48,614 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Olema Pharmaceuticals by 658.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 181,032 shares of the company's stock valued at $2,162,000 after buying an additional 157,171 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in Olema Pharmaceuticals by 80.5% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 212,246 shares of the company's stock valued at $1,237,000 after buying an additional 94,651 shares in the last quarter. SG Americas Securities LLC boosted its stake in Olema Pharmaceuticals by 33.8% in the 4th quarter. SG Americas Securities LLC now owns 17,475 shares of the company's stock valued at $102,000 after buying an additional 4,419 shares in the last quarter. Finally, Vontobel Holding Ltd. bought a new position in Olema Pharmaceuticals in the 4th quarter valued at $62,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Olema Pharmaceuticals Price Performance

Shares of OLMA stock traded up $0.02 on Friday, reaching $4.71. 479,940 shares of the stock were exchanged, compared to its average volume of 861,598. The stock has a market cap of $321.98 million, a PE ratio of -2.15 and a beta of 2.03. Olema Pharmaceuticals, Inc. has a one year low of $2.86 and a one year high of $16.62. The stock has a 50 day moving average price of $4.29 and a 200 day moving average price of $6.12.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. On average, research analysts expect that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

OLMA has been the subject of several research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research report on Monday, April 28th. The Goldman Sachs Group cut their price objective on Olema Pharmaceuticals from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday. JPMorgan Chase & Co. cut their price objective on Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating for the company in a research report on Friday, March 28th. Finally, Oppenheimer dropped their target price on Olema Pharmaceuticals from $25.00 to $22.00 and set an "outperform" rating for the company in a research report on Wednesday.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.